In Canada, GlaxoSmithKline has advised that the concomitant use of Paxil [paroxetine] and Orap [pimozide] is contraindicated

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1062, 2005-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

In Canada, a Public Advisory warning against the concomitant use of Paxil [paroxetine] or Paxil controlled-release (CR) and Orap [pimozide]

By  

Reactions Weekly, Vol. 1, Iss. 1063, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Health Canada has approved GlaxoSmithKline's controlled-release formulation of paroxetine

By  

Inpharma, Vol. 1, Iss. 1420, 2004-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

GlaxoSmithKline (GSK), in consultation with Health Canada, has issued a precautionary recall of one lot of Infanrix Hexa

By  

Reactions Weekly, Vol. 1, Iss. 1428, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

An amended lawsuit has been filed against pharmaceutical giant GlaxoSmithKline

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 388, 2002-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

GlaxoSmithKline's candidate paediatric pneumococcal vaccine GSK 1024850A [Synflorix] has the potential to offer increased protection

By  

Inpharma, Vol. 1, Iss. 1643, 2008-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite